Reduced Brain Norepinephrine and Dopamine Release in Treatment-Refractory Depressive Illness
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
In accordance with the monoamine hypothesis, a deficit in brain norepinephrine and dopamine exists in patients with depressive illness and the brains of these patients use an energy source other than glucose, a situation that is normalized following the acute pharmacological blockade of the norpinephrine transporter with the tricyclic antidepressant, desipramine.
Abstract
In accordance with the monoamine hypothesis, a deficit in brain norepinephrine and dopamine exists in patients with depressive illness. Moreover, the brains of these patients use an energy source other than glucose, a situation that is normalized following the acute pharmacological blockade of the norepinephrine transporter with the tricyclic antidepressant, desipramine.
